Lantheus price target lowered to $120 from $134 at JonesResearch

JonesResearch lowered the firm’s price target on Lantheus (LNTH) to $120 from $134 and keeps a Buy rating on the shares following the Q1 report. With Pylarify facing competitive pressure and its net sales down 0.5% year-over- year, an ongoing business reorganization and reduced fiscal 2025 earnings guidance, the stock has faced significant negative pressure, the analyst tells investors in a research note. The firm acknowledges near-term concerns over emerging PSMA-PET competition and potential increased operating expenses arising from recent acquisitions, but continues to have confidence in the medium- to long-term potential of Lantheus’ radiopharmaceutical pipeline. It expects strong execution and improved margins following the completion of acquisitions and divestitures.